August 14, 2015.
The US biosimilars market will be worth $11bn by 2020 and biosimilars will account for 4% to 10% of the biologics market total by 2020, according to ReportsnReports' Global & USA Biosimilar Market Analysis to 2021.
With the expected patent expiration of twelve biologics by 2020, biosimilars are expected to competitively penetrate the biologic's market. By 2019, 50% of the biologics market will belong to off-patent drugs, states the report, with the top five biologics targeted by biosimilar developers being Avastin, Enbrel, Herceptin, Humira and Rituxan, which together generate revenues of about $50 billion annually.
Can Data and AI Deliver Whole-Person Health?
July 9th 2024Executives in the life sciences and medical device industries see promise in artificial intelligence (AI) and medical technologies, but must also navigate the changing healthcare ecosystem, varied stakeholder needs, and the impact of AI on market access and commercialization strategies.